Earlier this year, the DEA responded to President Biden’s directive to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act. This pivotal change, if finalized, would reclassify marijuana as a drug with moderate to low potential for dependence, strictly for medical use. 

Chapters

00:00 Introduction to Workplace Issues and Cannabis Rescheduling 05:06 Understanding the Rescheduling Process of Cannabis 09:48 Implications of Rescheduling for Employers 15:07 Legal Challenges and Considerations for Healthcare Employers 19:50 Navigating Drug Testing and Employee Policies 24:51 Conclusion and Future Considerations